Study summary
Tebentafusp doubled 5-year survival in metastatic uveal melanoma
16%alive at 5 years with tebentafusp, vs 8%
What was tested
Final 5-year results of the phase 3 trial of tebentafusp, an immune drug that links T cells to melanoma cells, against doctor's choice of pembrolizumab, ipilimumab or dacarbazine, in previously untreated people with the HLA-A*02:01 tissue type.
What they found
- Median survival was 21.6 months vs 16.9 months.
- 16% were alive at 5 years vs 8%.
- Benefit held even in people whose scans showed growth.
What it means
The standard first treatment for people with the HLA-A*02:01 tissue type, about half of patients.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.